Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

Print Friendly, PDF & Email

This article explains both MNGIE and a new drug targetted to help MNGIE.


BOSTON, Jan. 8, 2020 /PRNewswire/ — Entrada Therapeutics Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). “MNGIE […]